First 2022 GaBI Journal issue highlights
No need for systematic switch studies to demonstrate interchangeability of biosimilars
Biotherapeutic products in the European Pharmacopoeia: have all challenges been tackled?
Challenges in the manufacture, storage, distribution and regulation of traditional and novel vaccines
Long-acting insulin analogues. Drug selection by means of the System of Objectified Judgement Analysis (SOJA)
Biosimilarity is not a transitive property: implication for interchangeability, naming and pharmacovigilance
Structural characterization methods for biosimilars: fit-for-purpose, qualified or validated
Source URL: https://gabi-journal.net/2022-1-gabi-journal-table-of-contents.html
Copyright ©2022 GaBI Journal unless otherwise noted.